TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05062889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Leucovorin
Description: 200 mg/sqm iv over 2 hours, day 1. To be repeated every two weeks for a maximum of 12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Leucovorin
Description: 200 mg/sqm iv over 2 hours, day 1. To be repeated every two weeks for a maximum of 12 cycles.
Study: NCT04323774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AYA-RISE Adolescents and Young Adults Risk Information and Screening Education
Description: A chatbot is a computer program that can chat with humans. The text the chatbot uses to talk with humans was created by real people, but the chatbot itself is not a real person. A company called Clear Genetics developed the original chatbot and patient portal, and this study team customized it for this research study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard clinical visit for genetic counseling
Description: Standard clinical visit for genetic counseling and follow up
Study: NCT06379217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-PSMA-11
Description: \[68Ga\]Ga-PSMA-11 will be administered as a single intravenous dose of approximately 150 MBq (4 mCi) to be administered during baseline imaging and approximately 7 weeks after last RLT dose. Administered dose should not be lower than 111 MBq (3 mCi) or higher than 259 MBq (7 mCi)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-PSMA-11
Description: \[68Ga\]Ga-PSMA-11 will be administered as a single intravenous dose of approximately 150 MBq (4 mCi) to be administered during baseline imaging and approximately 7 weeks after last RLT dose. Administered dose should not be lower than 111 MBq (3 mCi) or higher than 259 MBq (7 mCi)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-PSMA-11
Description: \[68Ga\]Ga-PSMA-11 will be administered as a single intravenous dose of approximately 150 MBq (4 mCi) to be administered during baseline imaging and approximately 7 weeks after last RLT dose. Administered dose should not be lower than 111 MBq (3 mCi) or higher than 259 MBq (7 mCi)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]GA-DOTA-TATE
Description: \[68Ga\]Ga-DOTA-TATE will be administered as a single intravenous dose to be administered during baseline imaging and approximately 7 weeks after last RLT dose, within a range of 100-200MBq (2.7-5.4 mCi)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]GA-DOTA-TATE
Description: \[68Ga\]Ga-DOTA-TATE will be administered as a single intravenous dose to be administered during baseline imaging and approximately 7 weeks after last RLT dose, within a range of 100-200MBq (2.7-5.4 mCi)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]GA-DOTA-TATE
Description: \[68Ga\]Ga-DOTA-TATE will be administered as a single intravenous dose to be administered during baseline imaging and approximately 7 weeks after last RLT dose, within a range of 100-200MBq (2.7-5.4 mCi)
Study: NCT05062889

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1000 mg/sqm/bid per os from day 1 to day 14. To be repeated every 3 weeks until 8 cycles. Available as 500 and 150 mg tablets.
Study: NCT06379217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-NeoB
Description: \[68Ga\]Ga-NeoB will be administered as a single intravenous dose to be administered during baseline imaging and approximately 7 weeks after last RLT dose.within a range of 150-250 MBq (4.1-6.8 mCi).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-NeoB
Description: \[68Ga\]Ga-NeoB will be administered as a single intravenous dose to be administered during baseline imaging and approximately 7 weeks after last RLT dose.within a range of 150-250 MBq (4.1-6.8 mCi).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-NeoB
Description: \[68Ga\]Ga-NeoB will be administered as a single intravenous dose to be administered during baseline imaging and approximately 7 weeks after last RLT dose.within a range of 150-250 MBq (4.1-6.8 mCi).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-PSMA-617
Description: \[177Lu\]Lu-PSMA-617 will be administered as an intravenous infusion at a dose of 7.4 GBq (200mCi) (+/- 10%), every 6 weeks for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-DOTA-TATE
Description: \[177Lu\]Lu-DOTA-TATE will be administered as an intravenous infusion at a dose of 7.4 GBq (200mCi) (+/- 10%) every 6 weeks for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-NeoB
Description: \[177Lu\]Lu-NeoB will be administered as an intravenous infusion at a dose of 9.25 GBq (250mCi) every 6 weeks for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Lysine HCl-L-Arginine HCl, 2.5 %,
Description: sterile solution for infusion Lysine HCl-Arginine HCl, 2.5 % (1L)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone (GnRH) analogues
Description: Anatomical Therapeutic Chemical \[ATC\] code L02AE

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone (GnRH) analogues
Description: Anatomical Therapeutic Chemical \[ATC\] code L02AE

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone (GnRH) analogues
Description: Anatomical Therapeutic Chemical \[ATC\] code L02AE

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH antagonists
Description: abarelix, degarelix, or relugolix

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH antagonists
Description: abarelix, degarelix, or relugolix

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH antagonists
Description: abarelix, degarelix, or relugolix

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiemetics & antinauseants
Description: ATC code A04A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Description: ATC code A03FA01
Study: NCT06447142

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Open kinetic chain strengthening exercise
Description: A web-based 8-week exercise program consisting of stretching exercises, open kinetic chain strengthening exercises, and functional exercises for the knee and hip will be performed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Closed kinetic chain strengthening exercise
Description: A web-based 8-week exercise program consisting of stretching exercises, closed kinetic chain strengthening exercises, and functional exercises for the knee and hip will be performed.
Study: NCT06049797

Intervention type: DRUG
Intervention: Fezolinetant
Description: Oral

Intervention type: DRUG
Intervention: Paroxetine
Description: Oral

Intervention type: DRUG
Intervention: Citalopram
Description: Oral

Intervention type: DRUG
Intervention: Escitalopram
Description: Oral
Study: NCT05062889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 165 mg/sqm iv over 60 minutes, day 1. To be repeated every two weeks for a maximum of 12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/Tipiracil
Description: 35 mg/m2/bid per os days 1-5 and 8-12. To be repeated every 4 weeks until 6 cycles. Available as 20 and 15 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 4 mg/kg iv over 30 minutes, day 1 (loading dose: 6 mg/kg iv over 90 minutes). To be repeated every two weeks for a maximum of 12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: 300 mg (two 150 mg tablets)/bid orally twice daily (approximately 8 to 12 hours between doses with or without a meal) for a maximum of 12 biweekly cycles.
Study: NCT05949710

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic exercise(AE)
Description: The participants will receive AE three times per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic exercise(AE)
Description: The participants will receive AE three times per week.
Study: NCT06398275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam 20 MG Injection [Byfavo]
Description: Remimazolam 0.1 mg/kg intravenous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Description: NaCl 0.9% 0.04 mL/kg
Study: NCT03541486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbate
Description: 75 gram infusion daily (M-F) on days when radiation therapy is administered. The infusion occurs during the 'beam on' of the radiation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 600 mg/m2 once weekly for up to weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 600 mg/m2 once weekly for up to weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Prescribed to 50 Gy in 25 fractions. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Prescribed to 50 Gy in 25 fractions. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.
Study: NCT06483191

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: A half-day pre-operative virtual ACT group workshop, booster post-operative ACT text messages once a week for 6 weeks and a telephone follow-up with a physiotherapist at 6-8 weeks (all in addition to standard care).
Study: NCT06049797

Intervention type: DRUG
Intervention: Desvenlafaxine
Description: Oral

Intervention type: DRUG
Intervention: Venlafaxine
Description: Oral

Intervention type: DRUG
Intervention: Gabapentin
Description: Oral
Study: NCT06550232

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Papaverine
Description: Within 30-minutes prior to catheter insertion, women in the intervention group will receive IV-papaverine 80 mg in 100 ml 0.9% saline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: I.V Sallne
Study: NCT06049797

Intervention type: DRUG
Intervention: Clonidine
Description: Oral

Intervention type: DRUG
Intervention: Pregabalin
Description: Oral

Intervention type: DRUG
Intervention: Oxybutynin
Description: Oral
Study: NCT05033522

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloStim® immunotherapy
Description: 3 cycles of intradermal and intravenous administrations
Study: NCT06049797

Intervention type: DRUG
Intervention: Any other SSRI/SNRI not already specified
Description: Oral

Intervention type: DRUG
Intervention: Any other non-hormonal pharmacologic therapy prescribed for the treatment of VMS not included in a category above
Description: Oral
Study: NCT05831046

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ED management software
Description: Patients utilize software after being screened, but prior to being re-evaluated by physician
Study: NCT05746390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Alone
Description: See Home Alone description.
Study: NCT05410730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1501
Description: SHR-1501 single agent dose escalation, and in combination of BCG or SHR-1316.
Study: NCT05781152

Intervention type: DRUG
Group type: OTHER
Intervention: Anti-TNF therapy
Description: Use of anti-TNF therapy for children and adolescents with newly diagnosed Crohn's disease guided by a clinical decision support tool
Study: NCT06381674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular therapy for mTBI augmented with audio and visual real-time biofeedback
Description: During physical therapy sessions participants will wear sensors on their head, chest, waist, and feet for real-time instrumented audio and visual biofeedback on quality of therapeutic exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular therapy for mTBI
Description: During physical therapy sessions participants will go through vestibular therapeutic exercise WITHOUT audio and visual real-time biofeedback.
Study: NCT06800131

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hepatitis B Vaccine administered trans-dermally via Microneedle Array Patch (MAP)
Description: A total of 40 subjects will be enrolled, 30 subjects administered trans-dermally via Microneedle Array Patch (MAP).
Study: NCT04904276

Intervention type: DRUG
Intervention: Fostamatinib
Description: Fostamatinib disodium

Intervention type: DRUG
Intervention: Fostamatinib
Description: Fostamatinib disodium
Study: NCT05033522

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX regimen
Description: Comparative arm: Physician Choice of FOLFOX4 chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Comparative arm: Physician Choice of Sorafenib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib
Description: Comparative Arm: Physician's Choice of Levantinib
Study: NCT06800131

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator vaccine via intramuscular injection
Description: 10 subjects administered with active comparator vaccine via intramuscular injection.
Study: NCT05935657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: 0.075 mg/kg Remimazolam bolus infusion for 1 min, then 0.1\~1.0 mg/kg/h continuous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 1 mcg/kg Dexmedetomidine infusion for 10 min, then 0.2\~0.7 mcg/kg/h continuous infusion
Study: NCT06027814

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation and mHealth (PN+mHealth)
Description: Intervention consists of patient navigation with the mHealth adherence application facilitating telehealth visits, two-way chats, video-DOT, and delivery of financial incentives via smartphone.
Study: NCT05425446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DONQ52
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DONQ52
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DONQ52
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DONQ52
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DONQ52
Description: Subcutaneous (SC) injection
Study: NCT06798831

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pertussis containing vaccine
Description: Recombinant acellular pertussis (aP) vaccine (containing 5 µg of geneticallydetoxified pertussis toxin (PTgen),
Study: NCT05174520

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Physical Therapy
Description: Routine physical therapy will be provided to group A for 25 minutes thrice a week for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique
Description: Muscle Energy technique along with Routine physical therapy will be provided to group B for40 minutes thrice a week for 4 weeks.
Study: NCT05739370

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Problem-Solving Therapy for Older Adults
Description: Problem-Solving Therapy for Older Adults (Ger-iPST) is an 8-week online psychotherapy program with online therapist support delivered through the Online Psycho Therapy Tool (OPTT). Ger-iPST has several evidence-based elements tailored to the specific needs of older adults, including relevant content (e.g. aging-related examples); process adaptations (e.g. more repetition); and digital usability modifications (e.g. high-contrast text).~Ger-iPST contains therapy modules assigned weekly and accessible at any time during the week. Modules begin with a brief, guided mindfulness relaxation exercise, followed by approximately 20 slides taking, on an average 1 hour to complete. Each module highlights a different step of Psychotherapy (PST) and includes an overview of a new skill, interactive activities and examples. A homework exercise designed to guide participants in applying a new PST skill exercise is submitted through the platform, and a clinician will provide personalized feedback.
Study: NCT04516057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabilone
Description: After the screening period, participants randomized to the nabilone arm will receive nabilone for 8 weeks. Participants will then be followed for 8 weeks following completion of the study treatment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After the screening period, participants randomized to the placebo arm will receive placebo capsules for 8 weeks. Participants will then be followed for 8 weeks following completion of the study treatment.
Study: NCT05074810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avutometinib and sotorasib
Description: The RP2D of avutometinib + sotorasib determined in Part A will be used in Part B dose expansion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avutometinib and sotorasib
Description: The RP2D of avutometinib + sotorasib determined in Part A will be used in Part B dose expansion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avutometinib and sotorasib
Description: The RP2D of avutometinib + sotorasib determined in Part A will be used in Part B dose expansion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avutometinib and sotorasib and defactinib
Description: The RP2D of avutometinib + sotorasib + defactinib determined in Part A will be used in Part B dose expansion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avutometinib and sotorasib and defactinib
Description: The RP2D of avutometinib + sotorasib + defactinib determined in Part A will be used in Part B dose expansion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avutometinib and sotorasib and defactinib
Description: The RP2D of avutometinib + sotorasib + defactinib determined in Part A will be used in Part B dose expansion
Study: NCT05298358

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RIC alloBMT w PTCy in refractory SSc
Description: The preparative regimen:~* Thymoglobulin 0.5 mg/kg IV day -9~* Thymoglobulin 2 mg/kg IV Days -8, -7~* Cyclophosphamide (Cy) 14.5 mg/kg IV Days -6,-5~* Fludarabine 30 mg/m2 IV Days -6, -5, -4, -3,-2~* Total body irradiation (TBI) 400cGy~* Day 0- infusion of unmanipulated bone marrow~The GVHD prophylaxis regimen:~* Cy 50 mg/kg IV Days 3, 4~* Tacrolimus (FK-506) (IV or oral (po)) beginning Day 5 with dose adjusted to maintain a trough level of 5-15 ng/mL. Sirolimus may be substituted for tacrolimus.~* Mycophenolate mofetil (MMF) 15 mg/kg po TID, maximum dose 1 g po TID Day 5 - Day 35~* Filgrastim (G-CSF) 5 µg/kg SQ daily beginning Day 5 until absolute neutrophil (ANC) is greater than 1000/µl over at least 2 days.~Supportive care:~* Mesna- 10 mg/kg/ IV Day 3, 4~* Patients will receive infection prophylaxis and treatment according to institutional guidelines.
Study: NCT05566249

Intervention type: DEVICE
Intervention: ArtiSential
Description: Articulating laparoscopic instrument
Study: NCT06798831

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pertussis containing vaccine
Description: Recombinant acellular pertussis (aP) vaccine (containing 5 µg of geneticallydetoxified pertussis toxin (PTgen),
Study: NCT06797882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride- potassium iodide
Description: SDF , Riva Star, SDI Limited., Australia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride varnish
Description: Duraphat varnish®, Colgate-Palmolive (UK) Ltd.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9 % saline
Description: Standard oral hygiene instructions every 3 months and application of Normal Saline for every 6 months
Study: NCT06798220

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Breakfast
Description: In this intervention, participants are offered a traditional breakfast (consisting of unprocessed or minimally processed foods), and postprandial appetite regulation is evaluated. Traditional breakfast includes chicken egg (boiled), white cheese (full-fat), white bread, black and green olives, tomatoes, cucumbers, and freshly squeezed orange juice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UPF Breakfast
Description: In this intervention, participants are offered an ultra-processed breakfast, and postprandial appetite regulation is evaluated. Ultra-processed breakfast includes pan-fried beef sausage (without oil), packaged sandwich bread, tomato-based ketchup, and packaged orange juice.
Study: NCT06800066

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Purchase Behavior - (Non-CBD ads)
Description: Participants will complete 1 shopping visit and will be randomly assigned to one of 2 conditions: 1) non-CBD advertising (control condition) or 2) CBD advertising (experimental condition). Each condition will have approximately 20 advertisements. In each condition, the Participant will be asked to purchase 3 products.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Purchase Behavior - (CBD ads)
Description: Participants will complete 1 shopping visit and will be randomly assigned to one of 2 conditions: 1) non-CBD advertising (control condition) or 2) CBD advertising (experimental condition). Each condition will have approximately 20 advertisements. In each condition, the Participant will be asked to purchase 3 products.
Study: NCT06797973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Morphine
Description: 80 μg preservative-free morphine (0.2 ml) added to a single-shot spinal anaesthesia consisting of 11.5 mg hyperbaric bupivacaine and 10 μg fentanyl